Sign In

Login

Password

Forgot Password ? Sign Up

Gliflozine (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Gliflozine" in French language version.

refsWebsite
Global rank French rank
24nih.gov
4th place
12th place
12issn.org
57th place
4th place
12doi.org
2nd place
3rd place
4ahajournals.org
3,608th place
659th place
3nejm.org
2,374th place
298th place
2thelancet.com
2,393rd place
506th place
2diabetesjournals.org
low place
7,774th place
2biomedcentral.com
2,747th place
1,253rd place
1springer.com
274th place
223rd place
1nature.com
234th place
147th place
1europa.eu
68th place
67th place
1sciencedirect.com
149th place
80th place
1fda.gov
447th place
1,409th place

ahajournals.org

ahajournals.org

circ.ahajournals.org

biomedcentral.com

bmcpharmacoltoxicol.biomedcentral.com

cardiab.biomedcentral.com

diabetesjournals.org

diabetes.diabetesjournals.org

care.diabetesjournals.org

doi.org

dx.doi.org

  • Rosalba La Grotta, Chiara Frigé, Giulia Matacchione et Fabiola Olivieri, « Repurposing SGLT-2 Inhibitors to Target Aging: Available Evidence and Molecular Mechanisms », International Journal of Molecular Sciences, vol. 23, no 20,‎ , p. 12325 (ISSN 1422-0067, PMID 36293181, PMCID 9604287, DOI 10.3390/ijms232012325, lire en ligne, consulté le )
  • Chun-Ting Yang, Zi-Yang Peng, Yi-Chi Chen et Huang-Tz Ou, « Cardiovascular Benefits With Favorable Renal, Amputation and Hypoglycemic Outcomes of SGLT-2 Inhibitors in Type 2 Diabetes From the Asian Perspective: A Population-Based Cohort Study and Systematic Review », Frontiers in Endocrinology, vol. 13,‎ , p. 836365 (ISSN 1664-2392, PMID 35330915, PMCID 8940301, DOI 10.3389/fendo.2022.836365, lire en ligne, consulté le )
  • Sushrima Gan, Adem Y. Dawed, Louise A. Donnelly et Anand T. N. Nair, « Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials », Diabetes Care, vol. 43, no 8,‎ , p. 1948–1957 (ISSN 1935-5548, PMID 33534728, PMCID 7372059, DOI 10.2337/dc19-2419, lire en ligne, consulté le )
  • Matthew M. Y. Lee, Nazim Ghouri, Darren K. McGuire et Martin K. Rutter, « Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes », Diabetes Care, vol. 44, no 5,‎ , p. 1236–1241 (ISSN 1935-5548, PMID 33707305, DOI 10.2337/dc20-3007, lire en ligne, consulté le )
  • Jason T. Alexander, Erin M. Staab, Wen Wan et Melissa Franco, « Longer-term Benefits and Risks of Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: a Systematic Review and Meta-analysis », Journal of General Internal Medicine, vol. 37, no 2,‎ , p. 439–448 (ISSN 1525-1497, PMID 34850334, PMCID 8811049, DOI 10.1007/s11606-021-07227-0, lire en ligne, consulté le )
  • Takayoshi Kanie, Atsushi Mizuno, Yoshimitsu Takaoka et Takahiro Suzuki, « Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis », The Cochrane Database of Systematic Reviews, vol. 10, no 10,‎ , p. CD013650 (ISSN 1469-493X, PMID 34693515, PMCID 8812344, DOI 10.1002/14651858.CD013650.pub2, lire en ligne, consulté le )
  • Nuffield Department of Population Health Renal Studies Group et SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium, « Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials », Lancet (London, England), vol. 400, no 10365,‎ , p. 1788–1801 (ISSN 1474-547X, PMID 36351458, PMCID 7613836, DOI 10.1016/S0140-6736(22)02074-8, lire en ligne, consulté le )
  • Donna Shu-Han Lin, Jen-Kuang Lee et Wen-Jone Chen, « Clinical Adverse Events Associated with Sodium-Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals », The Journal of Clinical Endocrinology and Metabolism, vol. 106, no 7,‎ , p. 2133–2145 (ISSN 1945-7197, PMID 33895840, DOI 10.1210/clinem/dgab274, lire en ligne, consulté le )
  • Chu Lin, Xingyun Zhu, Xiaoling Cai et Wenjia Yang, « SGLT2 inhibitors and lower limb complications: an updated meta-analysis », Cardiovascular Diabetology, vol. 20, no 1,‎ , p. 91 (ISSN 1475-2840, PMID 33910574, PMCID 8082772, DOI 10.1186/s12933-021-01276-9, lire en ligne, consulté le )
  • Gen Mizutani, Takeshi Horii, Yoichi Oikawa et Koichiro Atsuda, « Real-world risk of lower-limb amputation associated with sodium-glucose cotransporter 2 inhibitors versus metformin: A propensity score-matched model analysis in Japan », Journal of Diabetes Investigation, vol. 13, no 12,‎ , p. 2000–2009 (ISSN 2040-1124, PMID 36124433, PMCID 9720178, DOI 10.1111/jdi.13906, lire en ligne, consulté le )
  • Louis Potier, Ronan Roussel, Gilberto Velho et Pierre-Jean Saulnier, « Lower limb events in individuals with type 2 diabetes: evidence for an increased risk associated with diuretic use », Diabetologia, vol. 62, no 6,‎ , p. 939–947 (ISSN 1432-0428, PMID 30809716, DOI 10.1007/s00125-019-4835-z, lire en ligne, consulté le )
  • Elisa Marilly, Judith Cottin, Natalia Cabrera et Catherine Cornu, « SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits », Diabetologia, vol. 65, no 12,‎ , p. 2000–2010 (ISSN 1432-0428, PMID 35925319, DOI 10.1007/s00125-022-05773-8, lire en ligne, consulté le )

europa.eu

ema.europa.eu

  • European Medicines Agency, Forgixa

fda.gov

issn.org

portal.issn.org

  • Rosalba La Grotta, Chiara Frigé, Giulia Matacchione et Fabiola Olivieri, « Repurposing SGLT-2 Inhibitors to Target Aging: Available Evidence and Molecular Mechanisms », International Journal of Molecular Sciences, vol. 23, no 20,‎ , p. 12325 (ISSN 1422-0067, PMID 36293181, PMCID 9604287, DOI 10.3390/ijms232012325, lire en ligne, consulté le )
  • Chun-Ting Yang, Zi-Yang Peng, Yi-Chi Chen et Huang-Tz Ou, « Cardiovascular Benefits With Favorable Renal, Amputation and Hypoglycemic Outcomes of SGLT-2 Inhibitors in Type 2 Diabetes From the Asian Perspective: A Population-Based Cohort Study and Systematic Review », Frontiers in Endocrinology, vol. 13,‎ , p. 836365 (ISSN 1664-2392, PMID 35330915, PMCID 8940301, DOI 10.3389/fendo.2022.836365, lire en ligne, consulté le )
  • Sushrima Gan, Adem Y. Dawed, Louise A. Donnelly et Anand T. N. Nair, « Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials », Diabetes Care, vol. 43, no 8,‎ , p. 1948–1957 (ISSN 1935-5548, PMID 33534728, PMCID 7372059, DOI 10.2337/dc19-2419, lire en ligne, consulté le )
  • Matthew M. Y. Lee, Nazim Ghouri, Darren K. McGuire et Martin K. Rutter, « Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes », Diabetes Care, vol. 44, no 5,‎ , p. 1236–1241 (ISSN 1935-5548, PMID 33707305, DOI 10.2337/dc20-3007, lire en ligne, consulté le )
  • Jason T. Alexander, Erin M. Staab, Wen Wan et Melissa Franco, « Longer-term Benefits and Risks of Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: a Systematic Review and Meta-analysis », Journal of General Internal Medicine, vol. 37, no 2,‎ , p. 439–448 (ISSN 1525-1497, PMID 34850334, PMCID 8811049, DOI 10.1007/s11606-021-07227-0, lire en ligne, consulté le )
  • Takayoshi Kanie, Atsushi Mizuno, Yoshimitsu Takaoka et Takahiro Suzuki, « Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis », The Cochrane Database of Systematic Reviews, vol. 10, no 10,‎ , p. CD013650 (ISSN 1469-493X, PMID 34693515, PMCID 8812344, DOI 10.1002/14651858.CD013650.pub2, lire en ligne, consulté le )
  • Nuffield Department of Population Health Renal Studies Group et SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium, « Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials », Lancet (London, England), vol. 400, no 10365,‎ , p. 1788–1801 (ISSN 1474-547X, PMID 36351458, PMCID 7613836, DOI 10.1016/S0140-6736(22)02074-8, lire en ligne, consulté le )
  • Donna Shu-Han Lin, Jen-Kuang Lee et Wen-Jone Chen, « Clinical Adverse Events Associated with Sodium-Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals », The Journal of Clinical Endocrinology and Metabolism, vol. 106, no 7,‎ , p. 2133–2145 (ISSN 1945-7197, PMID 33895840, DOI 10.1210/clinem/dgab274, lire en ligne, consulté le )
  • Chu Lin, Xingyun Zhu, Xiaoling Cai et Wenjia Yang, « SGLT2 inhibitors and lower limb complications: an updated meta-analysis », Cardiovascular Diabetology, vol. 20, no 1,‎ , p. 91 (ISSN 1475-2840, PMID 33910574, PMCID 8082772, DOI 10.1186/s12933-021-01276-9, lire en ligne, consulté le )
  • Gen Mizutani, Takeshi Horii, Yoichi Oikawa et Koichiro Atsuda, « Real-world risk of lower-limb amputation associated with sodium-glucose cotransporter 2 inhibitors versus metformin: A propensity score-matched model analysis in Japan », Journal of Diabetes Investigation, vol. 13, no 12,‎ , p. 2000–2009 (ISSN 2040-1124, PMID 36124433, PMCID 9720178, DOI 10.1111/jdi.13906, lire en ligne, consulté le )
  • Louis Potier, Ronan Roussel, Gilberto Velho et Pierre-Jean Saulnier, « Lower limb events in individuals with type 2 diabetes: evidence for an increased risk associated with diuretic use », Diabetologia, vol. 62, no 6,‎ , p. 939–947 (ISSN 1432-0428, PMID 30809716, DOI 10.1007/s00125-019-4835-z, lire en ligne, consulté le )
  • Elisa Marilly, Judith Cottin, Natalia Cabrera et Catherine Cornu, « SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits », Diabetologia, vol. 65, no 12,‎ , p. 2000–2010 (ISSN 1432-0428, PMID 35925319, DOI 10.1007/s00125-022-05773-8, lire en ligne, consulté le )

nature.com

nejm.org

nih.gov

ncbi.nlm.nih.gov

  • Rosalba La Grotta, Chiara Frigé, Giulia Matacchione et Fabiola Olivieri, « Repurposing SGLT-2 Inhibitors to Target Aging: Available Evidence and Molecular Mechanisms », International Journal of Molecular Sciences, vol. 23, no 20,‎ , p. 12325 (ISSN 1422-0067, PMID 36293181, PMCID 9604287, DOI 10.3390/ijms232012325, lire en ligne, consulté le )
  • Chun-Ting Yang, Zi-Yang Peng, Yi-Chi Chen et Huang-Tz Ou, « Cardiovascular Benefits With Favorable Renal, Amputation and Hypoglycemic Outcomes of SGLT-2 Inhibitors in Type 2 Diabetes From the Asian Perspective: A Population-Based Cohort Study and Systematic Review », Frontiers in Endocrinology, vol. 13,‎ , p. 836365 (ISSN 1664-2392, PMID 35330915, PMCID 8940301, DOI 10.3389/fendo.2022.836365, lire en ligne, consulté le )
  • Sushrima Gan, Adem Y. Dawed, Louise A. Donnelly et Anand T. N. Nair, « Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials », Diabetes Care, vol. 43, no 8,‎ , p. 1948–1957 (ISSN 1935-5548, PMID 33534728, PMCID 7372059, DOI 10.2337/dc19-2419, lire en ligne, consulté le )
  • Matthew M. Y. Lee, Nazim Ghouri, Darren K. McGuire et Martin K. Rutter, « Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes », Diabetes Care, vol. 44, no 5,‎ , p. 1236–1241 (ISSN 1935-5548, PMID 33707305, DOI 10.2337/dc20-3007, lire en ligne, consulté le )
  • Jason T. Alexander, Erin M. Staab, Wen Wan et Melissa Franco, « Longer-term Benefits and Risks of Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: a Systematic Review and Meta-analysis », Journal of General Internal Medicine, vol. 37, no 2,‎ , p. 439–448 (ISSN 1525-1497, PMID 34850334, PMCID 8811049, DOI 10.1007/s11606-021-07227-0, lire en ligne, consulté le )
  • Takayoshi Kanie, Atsushi Mizuno, Yoshimitsu Takaoka et Takahiro Suzuki, « Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis », The Cochrane Database of Systematic Reviews, vol. 10, no 10,‎ , p. CD013650 (ISSN 1469-493X, PMID 34693515, PMCID 8812344, DOI 10.1002/14651858.CD013650.pub2, lire en ligne, consulté le )
  • Nuffield Department of Population Health Renal Studies Group et SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium, « Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials », Lancet (London, England), vol. 400, no 10365,‎ , p. 1788–1801 (ISSN 1474-547X, PMID 36351458, PMCID 7613836, DOI 10.1016/S0140-6736(22)02074-8, lire en ligne, consulté le )
  • Donna Shu-Han Lin, Jen-Kuang Lee et Wen-Jone Chen, « Clinical Adverse Events Associated with Sodium-Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals », The Journal of Clinical Endocrinology and Metabolism, vol. 106, no 7,‎ , p. 2133–2145 (ISSN 1945-7197, PMID 33895840, DOI 10.1210/clinem/dgab274, lire en ligne, consulté le )
  • Chu Lin, Xingyun Zhu, Xiaoling Cai et Wenjia Yang, « SGLT2 inhibitors and lower limb complications: an updated meta-analysis », Cardiovascular Diabetology, vol. 20, no 1,‎ , p. 91 (ISSN 1475-2840, PMID 33910574, PMCID 8082772, DOI 10.1186/s12933-021-01276-9, lire en ligne, consulté le )
  • Gen Mizutani, Takeshi Horii, Yoichi Oikawa et Koichiro Atsuda, « Real-world risk of lower-limb amputation associated with sodium-glucose cotransporter 2 inhibitors versus metformin: A propensity score-matched model analysis in Japan », Journal of Diabetes Investigation, vol. 13, no 12,‎ , p. 2000–2009 (ISSN 2040-1124, PMID 36124433, PMCID 9720178, DOI 10.1111/jdi.13906, lire en ligne, consulté le )
  • Louis Potier, Ronan Roussel, Gilberto Velho et Pierre-Jean Saulnier, « Lower limb events in individuals with type 2 diabetes: evidence for an increased risk associated with diuretic use », Diabetologia, vol. 62, no 6,‎ , p. 939–947 (ISSN 1432-0428, PMID 30809716, DOI 10.1007/s00125-019-4835-z, lire en ligne, consulté le )
  • Elisa Marilly, Judith Cottin, Natalia Cabrera et Catherine Cornu, « SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits », Diabetologia, vol. 65, no 12,‎ , p. 2000–2010 (ISSN 1432-0428, PMID 35925319, DOI 10.1007/s00125-022-05773-8, lire en ligne, consulté le )

pubmed.ncbi.nlm.nih.gov

  • Rosalba La Grotta, Chiara Frigé, Giulia Matacchione et Fabiola Olivieri, « Repurposing SGLT-2 Inhibitors to Target Aging: Available Evidence and Molecular Mechanisms », International Journal of Molecular Sciences, vol. 23, no 20,‎ , p. 12325 (ISSN 1422-0067, PMID 36293181, PMCID 9604287, DOI 10.3390/ijms232012325, lire en ligne, consulté le )
  • Chun-Ting Yang, Zi-Yang Peng, Yi-Chi Chen et Huang-Tz Ou, « Cardiovascular Benefits With Favorable Renal, Amputation and Hypoglycemic Outcomes of SGLT-2 Inhibitors in Type 2 Diabetes From the Asian Perspective: A Population-Based Cohort Study and Systematic Review », Frontiers in Endocrinology, vol. 13,‎ , p. 836365 (ISSN 1664-2392, PMID 35330915, PMCID 8940301, DOI 10.3389/fendo.2022.836365, lire en ligne, consulté le )
  • Sushrima Gan, Adem Y. Dawed, Louise A. Donnelly et Anand T. N. Nair, « Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials », Diabetes Care, vol. 43, no 8,‎ , p. 1948–1957 (ISSN 1935-5548, PMID 33534728, PMCID 7372059, DOI 10.2337/dc19-2419, lire en ligne, consulté le )
  • Matthew M. Y. Lee, Nazim Ghouri, Darren K. McGuire et Martin K. Rutter, « Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes », Diabetes Care, vol. 44, no 5,‎ , p. 1236–1241 (ISSN 1935-5548, PMID 33707305, DOI 10.2337/dc20-3007, lire en ligne, consulté le )
  • Jason T. Alexander, Erin M. Staab, Wen Wan et Melissa Franco, « Longer-term Benefits and Risks of Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: a Systematic Review and Meta-analysis », Journal of General Internal Medicine, vol. 37, no 2,‎ , p. 439–448 (ISSN 1525-1497, PMID 34850334, PMCID 8811049, DOI 10.1007/s11606-021-07227-0, lire en ligne, consulté le )
  • Takayoshi Kanie, Atsushi Mizuno, Yoshimitsu Takaoka et Takahiro Suzuki, « Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis », The Cochrane Database of Systematic Reviews, vol. 10, no 10,‎ , p. CD013650 (ISSN 1469-493X, PMID 34693515, PMCID 8812344, DOI 10.1002/14651858.CD013650.pub2, lire en ligne, consulté le )
  • Nuffield Department of Population Health Renal Studies Group et SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium, « Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials », Lancet (London, England), vol. 400, no 10365,‎ , p. 1788–1801 (ISSN 1474-547X, PMID 36351458, PMCID 7613836, DOI 10.1016/S0140-6736(22)02074-8, lire en ligne, consulté le )
  • Donna Shu-Han Lin, Jen-Kuang Lee et Wen-Jone Chen, « Clinical Adverse Events Associated with Sodium-Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals », The Journal of Clinical Endocrinology and Metabolism, vol. 106, no 7,‎ , p. 2133–2145 (ISSN 1945-7197, PMID 33895840, DOI 10.1210/clinem/dgab274, lire en ligne, consulté le )
  • Chu Lin, Xingyun Zhu, Xiaoling Cai et Wenjia Yang, « SGLT2 inhibitors and lower limb complications: an updated meta-analysis », Cardiovascular Diabetology, vol. 20, no 1,‎ , p. 91 (ISSN 1475-2840, PMID 33910574, PMCID 8082772, DOI 10.1186/s12933-021-01276-9, lire en ligne, consulté le )
  • Gen Mizutani, Takeshi Horii, Yoichi Oikawa et Koichiro Atsuda, « Real-world risk of lower-limb amputation associated with sodium-glucose cotransporter 2 inhibitors versus metformin: A propensity score-matched model analysis in Japan », Journal of Diabetes Investigation, vol. 13, no 12,‎ , p. 2000–2009 (ISSN 2040-1124, PMID 36124433, PMCID 9720178, DOI 10.1111/jdi.13906, lire en ligne, consulté le )
  • Louis Potier, Ronan Roussel, Gilberto Velho et Pierre-Jean Saulnier, « Lower limb events in individuals with type 2 diabetes: evidence for an increased risk associated with diuretic use », Diabetologia, vol. 62, no 6,‎ , p. 939–947 (ISSN 1432-0428, PMID 30809716, DOI 10.1007/s00125-019-4835-z, lire en ligne, consulté le )
  • Elisa Marilly, Judith Cottin, Natalia Cabrera et Catherine Cornu, « SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits », Diabetologia, vol. 65, no 12,‎ , p. 2000–2010 (ISSN 1432-0428, PMID 35925319, DOI 10.1007/s00125-022-05773-8, lire en ligne, consulté le )

sciencedirect.com

springer.com

link.springer.com

thelancet.com